Search Result

No matches for "

57198

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

By Targets:	Autophagy (8) Bcr-Abl (8) c-Kit (8) EGFR (1) FLAP (1) IRAK (1) Isocitrate Dehydrogenase (IDH) (1) Isotope-Labeled Compounds (2) Leukotriene Receptor (2) Ligands for Target Protein for PROTAC (1) PDGFR (8) Prostaglandin Receptor (1) Reference Standards (2) SARS-CoV (6)
By Research Areas:	Cancer (11) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Neurological Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15463

Imatinib Maximum Cited Publications 120 Publications Verification STI571; CGP-57148B	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-50946

Imatinib Mesylate Maximum Cited Publications 120 Publications Verification STI571 Mesylate; CGP-57148B Mesylate	c-Kit Bcr-Abl PDGFR Autophagy	Infection Neurological Disease Inflammation/Immunology Cancer
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC₅₀=100 nM) tyrosine kinases.

HY-18082

AGI-5198 15+ Cited Publications IDH-C35	Isocitrate Dehydrogenase (IDH)	Cancer
AGI-5198 (IDH-C35) is a potent and selective mutant IDH1 ^R132H inhibitor with an IC₅₀ of 0.07 μM.

HY-122908

Atuliflapon AZD5718	FLAP	Cardiovascular Disease
Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC₅₀ of 2 nM. Atuliflapon is used in the study for coronary artery disease .

HY-147264

Edecesertib GS-5718	IRAK	Inflammation/Immunology
Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research .

HY-15463S1

Imatinib-d4 STI571 d₄; CGP-57148B d₄	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₄ (STI571-d₄) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-15463S

Imatinib-d8 1 Publications Verification STI571-d₈; CGP-57148B-d₈	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-15463R

Imatinib (Standard) STI571 (Standard); CGP-57148B (Standard)	Reference Standards Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-105712

CGP 57698	Leukotriene Receptor	Inflammation/Immunology
CGP 57698 is an efficient CysLT receptor (K_i = 5.7 nM) antagonist. CGP 57698 can effectively counteract bronchoconstriction caused by LTD4. CGP 57698 can be used for research on asthma or allergic conditions .

HY-180498

NSC 57148	EGFR	Cancer
NSC 57148 is a selective Grb7 SH2 domain antagonist with an IC₅₀ value of 1.1 μM. NSC 57148 reduces cancer cell proliferation and migration. NSC 57148 is promising for research of Grb7-overexpressing malignancies such as breast and pancreatic cancers .

HY-50946R

Imatinib Mesylate (Standard) STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)	Reference Standards c-Kit Bcr-Abl PDGFR Autophagy	Cancer
Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC₅₀=100 nM) tyrosine kinases.

HY-111849

Imatinib carbaldehyde CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding moiety 1	Ligands for Target Protein for PROTAC	Cancer
Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-15463S3

Imatinib-13C,d3 STI571-¹³C,d₃; CGP-57148B-¹³C,d₃	Isotope-Labeled Compounds Autophagy SARS-CoV Bcr-Abl PDGFR c-Kit	Cancer
Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-U00355

YM158 free base YM-57158	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
YM158 free base is a potent and selective LTD₄ and TXA₂ receptor antagonist with pA₂ values of about 8.87 and 8.81, respectively.

HY-15463S2

Imatinib-d3 hydrochloride STI571-d3 hydrochloride; CGP-57148B-d3 hydrochloride	Autophagy Bcr-Abl c-Kit SARS-CoV PDGFR	Cancer
Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-132386S

Imatinib-d8 mesylate 1 Publications Verification STI571-d8 mesylate; CGP-57148B-d8 mesylate	Isotope-Labeled Compounds	Others
Imatinib-d₈ (mesylate) is the deuterium labeled Imatinib mesylate .

Cat. No.	Product Name	Chemical Structure

HY-15463S1

Imatinib-d4
Imatinib-d₄ (STI571-d₄) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-15463S3

Imatinib-13C,d3
Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

Imatinib-13C,d3

Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-15463S2

Imatinib-d3 hydrochloride
Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-132386S

Imatinib-d8 mesylate 1 Publications Verification
Imatinib-d₈ (mesylate) is the deuterium labeled Imatinib mesylate .

Host:	Mouse (4) Rabbit (1)
Reactivity:	Human (5) Rat (5) Mouse (3)
Application:	IHC-P (4) ICC/IF (3) IF-Tissue (1) IP (1) IHC-F (1) WB (3) ELISA (3)
Isotype:	IgG1,Kappa (1) IgG (1) IgG1 (1) IgG2a (1)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (5) Recombinant (1)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86026

	Cytokeratin Antibody (YA5718)	IHC-P, ELISA	Human, Mouse, Rat
	Cytokeratin Antibody (YA5718) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin.

HY-P86027

	Cadherin Antibody (YA5719)	IHC-P, ELISA	Human, Mouse, Rat
	Cadherin Antibody (YA5719) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cadherin.

HY-P87514

	CNPase Antibody (YA7198)	WB, IHC-P, IHC-F, IF-Tissue, ICC/IF	Human, Rat
	CNPase Antibody (YA7198) is a Mouse-derived and non-conjugated IgG1, Kappaappa monoclonal antibody, targeting to CNPase.

HY-P85506

	Mannose Phosphate Isomerase Antibody (YA5198) PMI1; CDG1B; FLJ39201; Mannose 6 phosphate isomerase; Mannose-6-phosphate isomerase; MANNOSEPHOSPHATE ISOMERASE; MGC94106; MPI; MPI_HUMAN; Phosphohexomutase; phosphomannose isomerase 1; Phosphomannose isomerase; PMI; PMI1.	WB, ICC/IF	Human, Rat
	Mannose Phosphate Isomerase Antibody (YA5198) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Mannose Phosphate Isomerase.

HY-P86106

	JNK2 Antibody (YA5798) MAPK9; JNK2; PRKM9; SAPK1A; Mitogen-activated protein kinase 9; MAP kinase 9; MAPK 9; JNK-55; Stress-activated protein kinase 1a; SAPK1a; Stress-activated protein kinase JNK2; c-Jun N-terminal kinase 2	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	JNK2 Antibody (YA5798) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JNK2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation:		* Country or Region:
* Applicant Name:		* Organization Name:
* Department:
* Email Address:		* Product Name:
Cat. No.:		* Requested quantity:
* Phone Number:
MCE Japan Authorized Agent:	ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.